Healthcare Sales & Marketing Network News: XP13512

Searching News Database: XP13512

HSMN NewsFeed - 5 Mar 2010
XenoPort Restructures to Focus on Key Programs
Biopharmaceuticals

HSMN NewsFeed - 13 Aug 2009
XenoPort Appoints Dennis Fenton to Board
Biopharmaceuticals Personnel

HSMN NewsFeed - 16 Sep 2008
GSK and XenoPort Announce Submission of New Drug Application Requesting FDA Approval of Solzira(TM) for Restless Legs Syndrome
Biopharmaceuticals

HSMN NewsFeed - 15 Jul 2008
XenoPort Appoints David A. Stamler, M.D., as Chief Medical Officer
Biopharmaceuticals Personnel

HSMN NewsFeed - 1 May 2008
XenoPort Appoints Vincent J. Angotti as Chief Commercialization Officer
Biopharmaceuticals Personnel

HSMN NewsFeed - 28 Feb 2008
XenoPort and GlaxoSmithKline Report Positive Top-Line Results of Final Pivotal Trial of XP13512/GSK1838262 for Restless Legs Syndrome
Biopharmaceuticals

HSMN NewsFeed - 25 Apr 2007
XenoPort Reports Positive Top-Line Phase 3 Trial Results of XP13512 in Restless Legs Syndrome
Biopharmaceuticals

HSMN NewsFeed - 8 Feb 2007
GlaxoSmithKline and XenoPort Announce Agreement on Late-Stage Compound for RLS and Neuropathic Pain
Biopharmaceuticals

HSMN NewsFeed - 22 Oct 2006
XenoPort Announces Positive Results From XP19986 Phase 2a Trial in Patients with Gastroesophageal Reflux Disease
Biopharmaceuticals Gastroenterology

HSMN NewsFeed - 14 Mar 2006
XenoPort Initiates Phase 3 Clinical Program for XP13512 as a Treatment for Restless Legs Syndrome
Biopharmaceuticals

Return to NewsFeed

Additional items found! 6

Members: click here for search results from The HSMN Archive (password required)

Members Archive contains 6 additional stories matching:
XP13512
(Password required)

FindReps - Find Great Medical Independent Sales Reps without recruiter fees.

FindReps - available on the Apple App Store for iPhone and iPad.